Nobumasa Yakushiji

The First Potent Subtype‐Selective Retinoid X Receptor (RXR) Agonist Possessing a 3‐Isopropoxy‐4‐isopropylphenylamino Moiety, NEt‐3IP (RXRα/β‐dual agonist)

Kayo Takamatsu, Atsushi Takano, Nobumasa Yakushiji et al. · ChemMedChem · 2008 · 49 citations

RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists

Hiroki Kakuta, Nobumasa Yakushiji, Ryosuke Shinozaki et al. · ACS Medicinal Chemistry Letters · 2012 · 45 citations · Full text

Pharmacotherapy, Glucose Tolerance, Insulin Signaling +17

Mechanism of Retinoid X Receptor Partial Agonistic Action of 1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1<i>H</i>-benzotriazole-5-carboxylic Acid and Structural Development To Increase Potency

Fuminori Ohsawa, Shoya Yamada, Nobumasa Yakushiji et al. · Journal of Medicinal Chemistry · 2013 · 43 citations · Full text

Pharmacotherapy, Experimental Pharmacology, Molecular Pharmacology +16

Reduction of Lipophilicity at the Lipophilic Domain of RXR Agonists Enables Production of Subtype Preference: RXRα‐Preferential Agonist Possessing a Sulfonamide Moiety

Kayo Takamatsu, Atsushi Takano, Nobumasa Yakushiji et al. · ChemMedChem · 2007 · 22 citations

Pharmacotherapy, Drug Resistance, Molecular Pharmacology +16

Replacing alkyl sulfonamide with aromatic sulfonamide in sulfonamide-type RXR agonists favors switch towards antagonist activity

Ken-ichi Morishita, Nobumasa Yakushiji, Fuminori Ohsawa et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 20 citations · Full text

Alkyl Sulfonamide, Biochemistry, Functional Selectivity +10